While lower-count MBL rarely progresses to CLL, high-count MBL progresses to CLL demanding therapy in a amount of 1% to 2% per annum. Significant-count MBL is distinguished from Rai 0 CLL based upon whether the B-cell rely is over or under 5 × 109/L. Although people today with each superior-depend MBL and CLL Rai stage 0 are at enhanced risk of in